v3.26.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Jun. 28, 2026
Dec. 31, 2025
Assets    
Cash and cash equivalents $ 976 $ 1,142
Short-term investments 10,723 12,454
Trade accounts receivable, net of allowance for doubtful accounts: 2026—$423; 2025—$427 12,490 11,874
Inventories 9,945 10,654
Current tax assets 3,702 3,967
Other current assets 3,522 2,808
Total current assets 41,358 42,898
Long-term investments 1,559 1,621
Property, plant and equipment, net of accumulated depreciation: 2026—$18,104; 2025—$17,386 19,029 19,317
Identifiable intangible assets, net 47,053 53,731
Goodwill 71,419 71,264
Noncurrent deferred tax assets and other noncurrent tax assets 10,774 9,699
Other noncurrent assets 9,939 9,631
Total assets 201,131 208,160
Liabilities and Equity    
Short-term borrowings, including current portion of long-term debt: 2026—$2,605; 2025—$2,997 2,699 3,154
Trade accounts payable 4,581 5,240
Dividends payable 2,451 2,445
Income taxes payable 653 3,103
Accrued compensation and related items 2,554 3,610
Other current liabilities 19,709 19,432
Total current liabilities 32,646 36,984
Long-term debt 60,495 61,641
Pension and postretirement benefit obligations 1,937 2,041
Noncurrent deferred tax liabilities 1,964 2,401
Other taxes payable 3,816 3,591
Other noncurrent liabilities 14,780 14,725
Total liabilities 115,639 121,385
Commitments and Contingencies
Common stock 482 481
Additional paid-in capital 95,033 94,469
Treasury stock (115,194) (115,015)
Retained earnings 112,087 114,610
Accumulated other comprehensive loss (7,218) (8,069)
Total Pfizer Inc. shareholders’ equity 85,190 86,476
Equity attributable to noncontrolling interests 302 299
Total equity 85,492 86,775
Total liabilities and equity $ 201,131 $ 208,160